검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 5-Fluoruracil |
Overview Company | NanoCarrier Co., Ltd. |
Overview Modality | ANTIBODY |
Overview Target | Locally Advanced Cancer in the Anal Regi |
Overview Indication | Locally Advanced Cancer in the Anal Region |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Management of patients with reduced dihydropyrimidine dehydrogenase activity receiving combined 5-fluoruracil-/capecitabine-based chemoradiotherapy.. 5‑Fluoruracil (5-FU) and its oral prodrug capecitabine are mainstays in combined chemoradiotherapy regimens. They are metabolized by dihydropyrimidine dehydrogenase (DPYD). Pathogenic variants of the DPYD gene cause a reduction in DPYD ac… |
Clinical Primary efficacy | ORR 72.7% |
Clinical ORR | 72.7% |
Clinical PFS | 10.41 |
Clinical OS | 19.7 |
Clinical Result source | ClinicalTrials.gov NCT04363801 |
Clinical Data Tier / Score | A · 61 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 5-Fluoruracil |
Overview Company | NanoCarrier Co., Ltd. |
Overview Modality | ANTIBODY |
Overview Target | Locally Advanced Cancer in the Anal Regi |
Overview Indication | Locally Advanced Cancer in the Anal Region |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Management of patients with reduced dihydropyrimidine dehydrogenase activity receiving combined 5-fluoruracil-/capecitabine-based chemoradiotherapy.. 5‑Fluoruracil (5-FU) and its oral prodrug capecitabine are mainstays in combined chemoradiotherapy regimens. They are metabolized by dihydropyrimidine dehydrogenase (DPYD). Pathogenic variants of the DPYD gene cause a reduction in DPYD ac… |
Clinical Primary efficacy | ORR 72.7% |
Clinical ORR | 72.7% |
Clinical PFS | 10.41 |
Clinical OS | 19.7 |
Clinical Result source | ClinicalTrials.gov NCT04363801 |
Clinical Data Tier / Score | A · 61 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
추천 비교
추천 비교